Having trouble accessing articles? Reset your cache.

Orexo, GAIA to develop digital therapeutic for opioid use disorder

Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product intended to enhance the use of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD).

For

Read the full 317 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE